

Application number

2120791

Registration number

TMA1186427

International Registration Number

1602891

Type(s)

Standard Characters

Category

Trademark

CIPO Status

REGISTERED

TM5 status

LIVE/REGISTRATION/Issued and Active



The trademark application has been registered with the Office.

Filed

2021-04-29

International Registration

2021-04-29

Registered

2023-06-21

Registration Expiry Date

2031-04-29

Registered Owner

Glaxo Group Limited
GSK Medicines Research
Centre
Gunnels Wood Road,
Stevenage SG1 2NY
UNITED KINGDOM

Agent

Index headings

KYVINZIO

Goods (Nice class & Statement)

- 5 (1) Pharmaceutical preparations for use as anti-infectives, none relating to oncology; pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficiency virus (HIV), human papilloma virus (HPV), respiratory syncytial virus (RSV), hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus, none relating to oncology; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders and their symptoms, none relating to oncology; pharmaceutical preparations for the treatment of immune system related diseases and disorders, namely immunosuppressants, none relating to oncology; pharmaceutical preparations for the treatment of immunologic diseases and disorders namely, autoimmune diseases and disorders, none relating to oncology; pharmaceutical preparations for the treatment of atherosclerosis, none relating to oncology; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders namely disorders of the endocrine system, namely growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management, none relating to oncology; pharmaceutical preparations for the treatment and prevention of cardiovascular, cardiopulmonary, cardio-renal and renal diseases and disorders, none relating to oncology; pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders namely arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, synovitis, none relating to oncology; pharmaceutical preparations for the treatment of blood-related diseases and disorders namely thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle-cell disease and its related disorders, anemias, sepsis and infections in and of the blood, none relating to oncology; pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, joint replacement and osteoarthritis, none relating to oncology; pharmaceutical preparations for use in ophthalmology, none relating to oncology; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and skin structure infections namely bacterial skin infections, fungal skin infections, viral skin infections and

BORDEN LADNER GERVAIS
LLP
World Exchange Plaza
100 Queen Street, Suite 1300
Ottawa
ONTARIO K1P1J9

Documents

[View documents](#)

parasitic skin infections, psoriasis, eczema and sexually transmitted diseases, none relating to oncology; pharmaceutical preparations for the treatment of hormonal related diseases and disorders namely hypogonadism, testosterone disorders, androgen disorders and estrogen disorders, none relating to oncology; pharmaceutical preparations for the treatment of gastrointestinal related diseases and disorders namely irritable bowel disorders and symptoms, digestive disorders and acid-related disorders, namely acidifiers to increase levels of gastric acid to decrease stomach pH for human purposes, none relating to oncology; pharmaceutical preparations for the treatment of sexual dysfunction namely erectile dysfunction, male and female sexual dysfunction disorders namely arousal disorder, pain disorder, desire disorder and orgasm disorder, none relating to oncology; pharmaceutical preparations for the treatment of genitourinary diseases namely urological diseases and disorders, none relating to oncology; pharmaceutical preparations for the treatment of gynaecological diseases and disorders namely amenorrhoea, dysmenorrhoea and infertility, none relating to oncology; pharmaceutical hormonal preparations namely corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations, none relating to oncology; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders, none relating to oncology; pharmaceutical preparations for the treatment of sexually transmitted diseases, inflammatory pelvic diseases, vasomotor symptoms, menopausal symptoms, endometriosis, uterine fibroids, Leiomyoma, endourological disorders and for the removal of renal calculi and the treatment of nephrolithiasis and urolithiasis, pre-eclampsia and pre-term labour, none relating to oncology; pharmaceutical preparations for the treatment of prostatitis, nephritis, cystitis, vaginitis, renal disease, none relating to oncology; pharmaceutical preparations for the treatment of premenstrual dysphoric disorder, premenstrual syndrome, male hypogonadism and hormonal disorders namely polycystic ovary syndrome, none relating to oncology; pharmaceutical preparations for the treatment of hepatological related diseases namely hepatitis, non-nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibroids, and cirrhosis, none relating to oncology; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia (male pattern baldness), none relating to oncology; pharmaceutical preparations for the treatment of psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia, and psychoses, none relating to oncology; pharmaceutical preparations for the treatment of damaged skin and tissue namely bee stings, sunburn, rashes, sores, corns, calluses and acne, none relating to oncology; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries, none relating to oncology; pharmaceutical preparations for the treatment of malaria, none relating to oncology;

pharmaceutical preparations for the treatment of tuberculosis, none relating to oncology; allergy medications, none relating to oncology; vaccines namely prophylactic and therapeutic vaccines for humans, none relating to oncology; pharmaceutical preparations for the treatment of neurological diseases and disorders namely Parkinsons disease, Alzheimers disease, Huntingtons disease, dementia, migraine, cerebral palsy, brain injury, spinal cord injury, seizure disorders, epilepsy, restless legs syndrome, pain, neuropathic pain, inflammatory-related pain, fibromyalgia, stroke, multiple sclerosis, insomnia, none relating to oncology; pharmaceutical preparations for the treatment of central nervous system diseases and disorders namely central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, depression and anxiety and their related disorders namely schizophrenia and psychoses, none relating to oncology; pharmaceutical preparations for the treatment of muscular dystrophy, none relating to oncology.

Claims

Priority Filing Date: April 19, 2021, Country or Office: UNITED KINGDOM, Application No. UK00003628645 in association with the same kind of goods

Recordals (known also as Footnotes)

CHANGE IN TITLE / CHANGEMENT EN TITRE:

TYPE OF CHANGE / GENRE DE CHANGEMENT: Name and Address / Nom et adresse

DATE REGISTERED / DATE DE L'ENREGISTREMENT: 2023-07-26

DATE OF CHANGE / DATE DE CHANGEMENT: 2023-06-28

COMMENTS / COMMENTAIRES: From: Glaxo Group Limited To: Glaxo Group Limited

Action History

Action	Action date	Due date	Comments
Filed	2021-04-29		Registration
International Registration	2021-04-29	2031-04-29	
Created	2021-07-14		
Formalized	2021-07-14		
Designation Notification - Madrid Protocol	2021-07-15	2023-01-15	
Limitation	2022-01-07		DP:2022-02-11
Partial Ceasing of Effect Received - No Amendments Required	2022-03-28		DP:2022-11-18 Effective date: 2022-02-18
Notification of Possible Opposition Sent	2022-05-16		
Search Recorded	2022-11-21		

Examiner's First Report	2022-11-21	2023-05-21	
Total Provisional Refusal	2022-11-21	2023-05-21	
Agent Changed	2023-01-10		From/De: To/A: 4
Approved	2023-03-02		APPROVED BY PROGRAM EX200M1
Approval Notice Sent	2023-03-02		APPROVED BY PROGRAM EX200M1
Advertised	2023-03-29		Vol.70 Issue 3570
Opposition Start Date Notice Sent	2023-03-29		Requested on 2023/03/29 03:30:20 in program jr500m1
Registration Pending	2023-06-21		
Registered	2023-06-21		
Statement of Grant of Protection Sent (following a Provisional Refusal)	2023-06-21		
Amendment to Registration	2023-07-27		DP:2023-07-26 Effective Date: 2023-06-28